Akin advised Pharmakon on its debt financing for Optinose’s sale to Paratek Pharmaceuticals
Akin advised Pharmakon Advisors, LP and its investment funds in providing, alongside other lenders including funds managed by Oaktree Capital Management, L.P., debt financing for the acquisition of Optinose, Inc. and its product, XHANCE® (fluticasone propionate), by Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on specialty therapies for specialists and community care providers.
As part of the transaction, Optinose, Inc. terminated and repaid in full all outstanding obligations to Pharmakon and its investment funds under a secured term loan upon the consummation of the acquisition.
The Akin team was led by Geoffrey Secol (Partner, Tax) and included Jake Gawlak (Associate) and Yossi Abadi (Associate). Additional support was provided by Stuart Leblang (Partner, Tax), David Snyder (Partner, Tax), Nate Brown (Partner, Health Care & Life Sciences), Kelly Cleary (Partner, Health Care & Life Sciences), and John Kwack (Associate).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.